食管鳞癌免疫治疗的研究进展
Research Progress in Immunotherapy of Esophageal Squamous Carcinoma
DOI: 10.12677/ACM.2022.121080, PDF,   
作者: 李彩耘：内蒙古民族大学第二临床学院，内蒙古 牙克石；曲洪澜：内蒙古林业总医院，内蒙古 牙克石
关键词: 食管鳞癌；免疫治疗；Esophageal Squamous Cell Carcinoma； Immunotherapy
摘要: 食管癌的主要病理类型为食管鳞癌，手术、化疗及放疗是其最主要的治疗方式。但是对于局部进展期患者，单纯手术或化疗无法达到理想的预后。近年来，免疫治疗领域的相关研究发展迅速，为食管癌患者的治疗带来了希望。在这篇综述中，就目前免疫检查点抑制剂应用于食管鳞癌的若干临床试验进行总结。
Abstract: The main pathological type of esophageal carcinoma is esophageal squamous cell carcinoma, and surgery, chemotherapy and radiotherapy are the main treatment methods. However, for locally advanced cases, surgery or chemotherapy alone does not achieve an ideal prognosis. In recent years, immunotherapy is a rapidly developing area of research, which brings promise for the treatment of patients with esophageal cancer. This review summarized the findings of clinical studies on the application of immunotherapy for esophageal squamous carcinoma.
文章引用：李彩耘, 曲洪澜. 食管鳞癌免疫治疗的研究进展[J]. 临床医学进展, 2022, 12(1): 545-548. https://doi.org/10.12677/ACM.2022.121080

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Yang, J. (2020) Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade. Frontiers in Oncology, 10, 1727. [Google Scholar] [CrossRef] [PubMed]
[3] Zeng, H., Zheng, R., Zhang, S., et al. (2016) Esophageal Cancer Statistics in China, 2011: Estimates Based on 177 Cancer Registries. Thoracic Cancer, 7, 232-237. [Google Scholar] [CrossRef] [PubMed]
[4] Zeng, H., Zheng, R., Guo, Y., et al. (2015) Cancer Survival in China, 2003-2005: A Population-Based Study. International Journal of Cancer, 136, 1921-1930. [Google Scholar] [CrossRef] [PubMed]
[5] Li, Y., Yu, L., Na, J., et al. (2017) Survival of Cancer Patients in Northeast China: Analysis of Sampled Cancers from Population-Based Cancer Registries. Cancer Research and Treatment, 49, 1106-1113. [Google Scholar] [CrossRef] [PubMed]
[6] Yang, W., Lei, C., Song, S., et al. (2021) Immune Checkpoint Blockade in the Treatment of Malignant Tumor: Current Statue and Future Strategies. Cancer Cell International, 21, Article Number: 589. [Google Scholar] [CrossRef] [PubMed]
[7] Karlsson, A.K. and Saleh, S.N. (2017) Checkpoint Inhibitors for Malignant Melanoma: A Systematic Review and Meta-Analysis. Clinical, Cosmetic and Investigational Dermatology, 10, 325-339. [Google Scholar] [CrossRef] 
[8] Glode, A.E. and May, M.B. (2021) Immune Checkpoint Inhibitors: Significant Advancements in Non-Small Cell Lung Cancer Treatment. American Journal of Health-System Pharmacy, 78, 769-780. [Google Scholar] [CrossRef] [PubMed]
[9] Zhang, Z., et al. (2021) A Single-Center, Prospective, Open-Label, Single-Arm Trial of Sintilimab with Paclitaxel and Carboplatin as a Neoadjuvant Therapy for Esophageal Squamous Carcinoma. Annals of Oncology, 32, S1042-S1043. [Google Scholar] [CrossRef] 
[10] Wang, J. (2021) A Prospective Study of Camrelizumab Monotherapy Following Definitive Concurrent Chemoradiotherapy in Patients with Unresectable Locally Advanced Esophageal Squamous Cell Cancer. Annals of Oncology, 32, S838. [Google Scholar] [CrossRef] 

为你推荐